$VTGN Cashflow Statement | Understand Stock

$VTGN

$0.17 +$0.00 (0.12%) Close

$VTGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of fixed assets
Stock-based compensation
Expense related to acquisition of Pherin Pharmaceuticals, Inc. recorded as an asset acquisition
Warrant modification expense
Amortization of operating lease right-of-use asset
Expense related to write-off of deferred offering costs
Accretion of marketable securities
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Security deposits
Other assets
Operating lease liability
Deferred sublicense revenue, net of deferred contract acquisition costs
License
Total deferred sublicense revenue, net of deferred contract acquisition costs

Accounts payable and accrued expenses
Net cash used in operating activities

Cash flows from investing activities:
Purchases of laboratory and other equipment
Cash used in acquisition of Pherin Pharmaceuticals, Inc. as an asset acquisition
Sales and maturities of marketable securities
Purchases of marketable securities
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from issuance of common stock and Series D Preferred stock
Net proceeds from issuance of common stock and warrants, including option exercises
Net proceeds from issuance of common stock, including option exercises
Net proceeds from exercise of warrants, net of underlying share registration expenses
Repayment of financing lease obligations
Issuance of note payable for insurance policy
Repayment of note payable
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Insurance premiums settled by issuing note payable
Acquisition of office equipment subject to financing lease
Purchases of equipment included in accounts payable
Fair value of common stock issued for acquisition of Pherin Pharmaceuticals, Inc.
Accrued dividends on Series B Preferred
Accrued dividends on Series B Preferred settled upon conversion by issuance of common stock
Cash paid for interest
Cash paid for income taxes

Comments